Coherus BioSciences (CHRS) – PRNewswire
-
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
-
Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
-
Essent Group Set to Join S&P MidCap 400; Coherus BioSciences, Patterson-UTI Energy to Join S&P SmallCap 600
-
Innovent Out-Licenses Commercial Rights for Avastin® Biosimilar to Coherus BioSciences in the United States and Canada
-
Bioeq Announces Coherus as Marketing and Distribution Partner for Its Biosimilar to Lucentis® (ranibizumab) in the U.S.
Back to CHRS Stock Lookup